Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD of LC51-0255 in healthy male subjects
NCT03174613Phase 1Completed
- Sponsor
- LG Chem
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing LC51-0255 with Placebo (2 arms). Primary endpoint: Maximum Tolerated Dose at Day 39. Started May 2017; status: completed.
02
Drugs
zectivimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03174613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174613.